Product nameAnti-JAK3 antibody
See all JAK3 primary antibodies
DescriptionRabbit polyclonal to JAK3
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Chimpanzee, Macaque monkey
Synthetic peptide corresponding to Human JAK3 aa 1100 to the C-terminus (C terminal) conjugated to keyhole limpet haemocyanin.
Database link: P52333
- This antibody gave a positive signal in TF-1 whole cell lysate
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab125296 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 125 kDa (predicted molecular weight: 125 kDa).|
FunctionTyrosine kinase of the non-receptor type, involved in the interleukin-2 and interleukin-4 signaling pathway. Phosphorylates STAT6, IRS1, IRS2 and PI3K.
Tissue specificityIn NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.
Involvement in diseaseDefects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:600802]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
DomainPossesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
modificationsTyrosine phosphorylated in response to IL-2 and IL-4.
Cellular localizationEndomembrane system. Wholly intracellular, possibly membrane associated.
- Information by UniProt
- EC 18.104.22.168 antibody
- JAK 3 antibody
- JAK L antibody
Anti-JAK3 antibody (ab125296) at 1 µg/ml (Milk blocking - 1%) + TF-1 (Human erythroleukaemic cell line) Whole Cell Lysate at 25 µg
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 125 kDa
Observed band size: 125 kDa
Exposure time: 8 minutes
This blot was produced using a 10% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 1% Milk before being incubated with ab125296 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution.
ab125296 has not yet been referenced specifically in any publications.